|
| |
| |
|
 |
Phosphagenics'
transdermal insulin clinical trial confirms successful delivery of insulin
across skin in humans |
Melbourne, Australia, 12 October
2006: Phosphagenics Limited (“Phosphagenics”) (ASX: POH; AIM: PSG) announced
today that it has received the final report of its Phase I transdermal insulin
clinical trial.
The final report confirms the conclusions of the interim results announced in
August, that Phosphagenics had successfully delivered insulin through the skin
in humans by means of its patented TPM-02/Insulin delivery system. The key
findings, as previously announced, were that TPM-02/Insulin, when applied as a
gel, delivered insulin through the skin and into the bloodstream and exerted a
physiological effect of lowering blood glucose levels. Importantly,
TPM-02/Insulin did not produce any adverse reactions.
A new finding, contained in the final study report, was the detection of
exogenous insulin (externally-applied insulin) in the circulation of volunteers
who received TPM-02/Insulin. This additional data, in conjunction with the blood
glucose, endogenous insulin and c-peptide results of the trial announced in
August, demonstrate the ability of TPM-02/Insulin to deliver insulin into the
blood stream to produce significant physiological effects.
ENDS…
About Phosphagenics’ Transdermal Carrier Technology
Phosphagenics’ patented transdermal carrier technology (TPM) utilises natural
dermal transport mechanisms to rapidly transport small and large molecules
across the skin without disrupting or damaging its surface.
The Company believes that the key advantages of this delivery system includes
the fact that it possesses anti-inflammatory and anti-erythema properties, thus
minimising skin irritation, and has the ability to provide a sustained systemic
delivery of a wide range of drugs – ranging from relatively small molecules
(e.g. morphine, fentanyl, oxycodone, atropine, estradiol, testosterone) to large
molecules (e.g. insulin and PTH) – from a single application. Additionally, the
TPM delivery technology can be cost-effectively manufactured in a wide range of
presentations (e.g. gel, paste, liquid and powder) adding value to existing
pharmaceuticals.
About Phosphagenics Limited
Phosphagenics is a Melbourne-based, globally driven biotechnology company
focused on the discovery of new and cost effective ways to enhance the
bioavailability, activity, safety and delivery of proven pharmaceutical and
nutraceutical products.
Phosphagenics’ core technology is built around the science and application of
phosphorylation, a process where the addition of a phosphate group has been
found to enhance the bioavailability, activity and safety of existing
pharmaceuticals and nutraceuticals, as well as to assist in the production of
drug delivery platforms.
Phosphagenics’ shares are listed on the Australian Stock Exchange (POH) and the
London Stock Exchange's Alternative Investment Market (PSG). An ADR – Level 1
program has been established in the US with the Bank of New York (PPGNY) for US
investors to trade in Phosphagenics’ stock on the ‘over-the-counter’ market.
For more information, please visit Phosphagenics’ web site at
www.phosphagenics.com
Contact details:
Phosphagenics Ltd
Dr Esra Ogru
Executive Director Research & Development
Ph: +61 3 9605 5900 or +61 (0) 402 080 846
Mr Harry Rosen
Managing Director
Ph: +61 3 9605 5900 or +61 (0)421 322 757
Northbank Communications
Gemma Bradley / Justine Lamond
Ph: +44 (0)20 3008 7550
g.bradley@northbankcommunications.com
/ j.lamond@northbankcommunications.com
| |
|
